. "3 Current Registry Activities." Developing a National Registry of Pharmacologic and Biologic Clinical Trials: Workshop Report. Washington, DC: The National Academies Press, 2006.
The following HTML text is provided to enhance online
readability. Many aspects of typography translate only awkwardly to HTML.
Please use the page image
as the authoritative form to ensure accuracy.
Developing a National Registry of Pharmacologic and Biologic Clinical Trials: Workshop Summary
TABLE 3–1 Required Data Fields for the DHHS Clinical Trial Registry at ClinicalTrials.gov
Unique Protocol ID Number
Study Sponsor
Verification Date
Brief Title (in lay language)
Brief Summary (in lay language)
Study Design, Study Phase, Study Type
Condition or Disease
Intervention
Study Status
Eligibility Criteria/Gender/Age
Location of Trial
Contact Information
Although ClinicalTrials.gov has been a valuable tool to enable patients and health care providers to understand the research occurring in various therapeutic areas and to locate clinical trials in which to enroll, it has certain limitations within its legislative mandate:
It applies only to serious and life-threatening conditions.
There is no mechanism to ensure compliance by all entities performing clinical trials.
It does not include disclosure of study results.
Required data fields are not always completed in an informative manner.
For these reasons, several groups have called for the mandatory registration of additional clinical trials as well as the registration of more extensive clinical trial information and the posting of a summary of clinical trial results. In addition, a number of clinical trial registries have been created in the public sector and by several pharmaceutical companies. The most prominent, and probably influential, proposals for registry requirements—by the International Committee of Medical Journal Editors (ICMJE), the international pharmaceutical industry and, most recently, the World Health Organization (WHO)—were presented at the workshop and are described below.
